Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2012

01-07-2012 | Thoracic Oncology

Vascular Endothelial Growth Factor Receptor 2 Gene Polymorphisms as Predictors for Tumor Recurrence and Overall Survival in Non-Small-Cell Lung Cancer

Authors: Faik G. Uzunoglu, MD, Caroline Kaufmann, Harriet Wikman, PhD, Cenap Güngör, DSc, Benjamin A. Bohn, MD, Michael F. Nentwich, MD, Matthias Reeh, MD, Klaus Pantel, Maximilian Bockhorn, PhD, Asad Kutup, MD, Oliver Mann, PhD, Jakob R. Izbicki, Yogesh K. Vashist, MD

Published in: Annals of Surgical Oncology | Issue 7/2012

Login to get access

Abstract

Purpose

VEGFR-2 gene displays several functional germline polymorphisms with impact on VEGFR-2 mediated angiogenesis. Our purpose was to evaluate VEGFR-2 polymorphisms as prognostic markers for tumor recurrence and overall survival (OS) in non-small-cell lung cancer (NSCLC).

Methods

In total, 209 Caucasian patients who had been surgically treated for NSCLC between 1996 and 2010 were included in this study. Genotyping of peripheral blood cells was performed by TaqMan® genotyping assays or polymerase chain reaction for five VEGFR-2 polymorphisms. Chi- square test, Kaplan–Meier estimator, and Cox regression hazard model were used to assess the prognostic value of VEGFR-2 polymorphisms.

Results

VEGFR-2+4422 (AC)10–14 polymorphism was identified as a positive prognostic marker for time to metastasis (11/12 vs. 11/11 (AC) repeats: hazard ratio (HR), 0.28; 95% confidence interval (CI), 0.11–0.75; p = 0.012) and OS (11/12 vs. 11/11 (AC) repeats: HR, 0.41; 95% CI, 0.21–0.82; p = 0.012) in squamous cell carcinoma. For adenocarcinoma, VEGFR-2−906 C>T (C/T vs. CC: HR, 0.19; 95% CI, 0.43–0.82; p = 0.027) and VEGFR-2−271 G>A (G/A vs. G/G: HR, 0.25; 95% CI, 0.07–0.86; p = 0.027) predicted longer time to local recurrence and VEGFR-2−906 C>T was a predictor for better OS (T/T vs. C/C: HR, 0.28; 95% CI, 0.09–0.84; p = 0.024).

Conclusions

VEGFR2 germline polymorphisms predict tumor recurrence and OS in NSCLC.
Literature
1.
O’Byrne KJ, Koukourakis MI, Giatromanolaki A et al. (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 82:1427–32.PubMedCrossRef
2.
Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol. 1995;177:57–63.PubMedCrossRef
3.
Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992;340:145–6.PubMedCrossRef
4.
Hicklin DJ, Ellis LM. Role Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol. 2005;23:3243–56.PubMedCrossRef
5.
Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87:694–701.PubMedCrossRef
6.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-39.PubMed
7.
Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997;79:233–69.PubMed
8.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.PubMedCrossRef
9.
Jantus-Lewintre E, Sanmartín E, Sirera R, et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011. 74(2):326–31.PubMedCrossRef
10.
11.
Wozniak A. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Crit Rev Oncol Hematol. 2011 (in press).
12.
An SJ, Chen ZH, Lin QX, Su J, Chen HJ, Lin JY, Wu YL. The −271 G > A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. BMC Cancer. 2009;9:144.PubMedCrossRef
13.
Hansen TF, Sorensen FB, Spindler KL, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch. 2010;456:251–60.PubMedCrossRef
14.
Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, Lipton JH. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2010;21:1179–88.PubMedCrossRef
15.
Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:856–62.PubMedCrossRef
16.
Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours. 7th edn. Wiley-Blackwell, Oxford.
17.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–72.PubMedCrossRef
18.
Kariyazono H, Ohno T, Khajoee V, et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res. 2004;56:953–9.PubMedCrossRef
19.
Abbott BD, Buckalew AR. Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. Dev Dyn. 2000;219:526–38.PubMedCrossRef
20.
Calderwood MS, Gannoun-Zaki L, Wellems TE, Deitsch KW. Plasmodium falciparum var genes are regulated by two regions with separate promoters, one upstream of the coding region and a second within the intron. J Biol Chem. 2003;278:34125–32.PubMedCrossRef
21.
Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999;274:13176–80.PubMedCrossRef
22.
Webb KE, Martin JF, Cotton J, Erusalimsky JD, Humphries SE. The 4830C > A polymorphism within intron 5 affects the pattern of alternative splicing occurring within exon 6 of the thrombopoietin gene. Exp Hematol. 2003;31:488–94.PubMedCrossRef
23.
Wang Y, Zheng Y, Zhang W, et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007;50:760–7.PubMedCrossRef
24.
Glubb DM, Cerri E, Giese A, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011;17:5257–67.PubMedCrossRef
Metadata
Title
Vascular Endothelial Growth Factor Receptor 2 Gene Polymorphisms as Predictors for Tumor Recurrence and Overall Survival in Non-Small-Cell Lung Cancer
Authors
Faik G. Uzunoglu, MD
Caroline Kaufmann
Harriet Wikman, PhD
Cenap Güngör, DSc
Benjamin A. Bohn, MD
Michael F. Nentwich, MD
Matthias Reeh, MD
Klaus Pantel
Maximilian Bockhorn, PhD
Asad Kutup, MD
Oliver Mann, PhD
Jakob R. Izbicki
Yogesh K. Vashist, MD
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2227-4

Other articles of this Issue 7/2012

Annals of Surgical Oncology 7/2012 Go to the issue

Urologic Oncology

Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection

Colorectal Cancer

The Relationship of Lymph Node Evaluation and Colorectal Cancer Survival After Curative Resection: A Multi-Institutional Study

Endocrine Tumors

Clinical Implication of Elastography as a Prognostic Factor of Papillary Thyroid Microcarcinoma

Gastrointestinal Oncology

The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture

Endocrine Tumors—Streaming Video

Robotic Transaxillary Thyroid Lobectomy of a Follicular Neoplasm

Colorectal Cancer

Compartmental Differences of Circulating Tumor Cells in Colorectal Cancer